TVGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 56.60%

Insider Buying (Last 12 Months): $2,460.00

Insider Selling (Last 12 Months): $1,747,332.00

Tevogen Bio Insider Trading History Chart

Tevogen Bio Share Price & Price History

^$1.80

▲ +0.08 (4.65%)

As of 10/21/2024 01:00 AM ET

Days: 30 | 90 | 365

Elon Musk Drops Stunning Bombshell?

From Paradigm Press | Ad

Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While delivering the death blow to some of the world’s BIGGEST companies. Why is no one talking about it?

Click here now to learn what was discussed in this closed-door event – and how to position yourself.

Tevogen Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/17/2024	Neal Flomenberg	Insider	Sell	1,078,600	$1.62	$1,747,332.00	4,254,302
6/12/2024	Kirti Desai	CFO	Buy	3,000	$0.82	$2,460.00	9,699,186

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company	Details
5/9/2024	Portland Global Advisors LLC	5,782,209	$21.68M	3.0%	N/A	36.550%

Data available starting January 2016

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Today's Range

Now: $1.80

$1.61

$2.00

50 Day Range

MA: $0.58

$0.26

$1.80

52 Week Range

Now: $1.80

$0.26

$21.09

Volume

19,606,995 shs

Average Volume

3,993,802 shs

Market Capitalization

$299.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Tevogen Bio?: Tevogen Bio's top insider investors include:
Kirti Desai (CFO)
Neal Flomenberg (Insider)
Learn More about top insider investors at Tevogen Bio.